SPTX · Seaport Therapeutics reported a Q3 2026 net loss of $26.4 million,…

Seaport Therapeutics reported a Q3 2026 net loss of $26.4 million, wider than the $22.5 million loss in Q3 2025, and in line with consensus expectations for a pre-revenue clinical-stage biotech. The key positive was positive topline data from the Phase 1 driving simulation trial for GlyphAllo, showing no next-morning driving impairment, which de-risks the program. Cash of $403.8 million funds operations into 2029 through multiple data readouts.

• Net loss of $26.4 million for Q3 2026 vs $22.5 million in Q3 2025.
• Cash, cash equivalents, and investments of $403.8 million as of September 30, 2026.
• Positive topline data from Phase 1 driving simulation trial of GlyphAllo: no next-morning driving impairment vs placebo.
• First patient dosed in Phase 2a trial of GlyphAgo in GAD and sleep disturbance.